Creative Biolabs Rolls Out Cutting-Edge Strategies for SARS-CoV-2 Drug Discovery
Creative Biolabs, Inc. a leading provider of biotech products and services in drug development, improves its drug discovery strategies and platforms for COVID-19. It now offers solutions spanning all areas of SARS-CoV-2 research, including antibody discovery, molecular diagnostic assay development, and drug evaluation.
November 29, 2021 /MarketersMEDIA/ —
Since the outbreak of COVID-19, considerable resources and efforts have been consumed to diagnose and treat this infectious pneumonia, which compels scientists to develop efficient antiviral products for SARS-CoV-2. Having been dedicated to the development of therapeutics, diagnostics, and vaccines for over 10 years, Creative Biolabs is able to streamline SARS-CoV-2 drug discovery services for researchers who need help in screening and identifying potential antiviral drugs.
“Our team has accumulated extensive experience when contributing to the research and control of the MERS epidemic in 2012, so we believe that we can also help this time. It is indeed the case that Creative Biolabs has developed related proteins, antibodies, and nucleic acid extraction kits at the first moment for COVID-19,” said a team member of Creative Biolabs.
Several strategies for SARS-CoV-2 are enhanced this time at Creative Biolabs, ranging from early diagnosis to drug evaluation:
Based on the full gene sequence analysis result of SARS-CoV-2, researchers can use molecular diagnostic assays for SARS-CoV-2 detection, which helps rapidly identify the infected in case of condition deterioration and disease transmission. Technologies that could be used to develop SARS-CoV-2 molecular diagnostic tools cover rRT-PCR, RT-PCR, RT-LAMP real-time RT-LAMP, and RNA imaging.
As neutralizing antibodies (nAbs) can specifically bind to the S-protein on the SARS-CoV-2 surface, developing neutralizing antibodies through polyclonal antibody technology is the first promising therapy. Researchers can discover neutralizing antibodies through animal immunization, hybridoma technique, and phage display and further develop nAbs drug candidates against SARS-CoV-2.
Drug evaluation is of vital importance in drug discovery. Cutting-edge screening and evaluation platforms for SARS-CoV-2 drugs have been developed by Creative Biolabs, such as reverse genetics systems, cell lines, spike pseudoviruses, animal models, and more to advance preclinical studies of SARS-CoV-2.
About Creative Biolabs
Creative Biolabs is the go-to company for high-quality biotechnology products and solutions. This life science company has years of experience in the field of drug discovery and evaluation and has globally earned a remarkable reputation due to the expert team, advanced facilities, flexible services and high-quality products, efficient customer support, wallet-friendly price, and trustworthy result.
Learn about more SARS-CoV-2 drug discovery, vaccine design, and in vitro diagnostic services by visiting the company’s website: https://sars-cov-2.creative-biolabs.com/.
Release ID: 89054759